EGFR and non-small cell lung carcinoma: The CNS objective response rate (ORR) of TKIs for NSCLC patients with EGFR-mutant and BMs was reported up to 70–93%, the median progression-free survival (PFS) and overall survival (OS) were 6.6 months and 15.9 months [9].